Part would like that to be true; a buyout with som
Post# of 72440
The other part of me wonders if IPIX will get the best value for their IP in that scenario. My gut says no. I think IPIX and its shareholders get the best returns and long term value with Leo's strategy to be like REGN. Maybe we sell one or two indications for cash now, but then we license the heavy hitters like B-ABSSSI, B GI tract indications, B dermatological indications and anything K related.
I dunno, I am just speculating here. Regardless of how it turns out in the end I am anxious for the first deal to be made, whatever it is. We need the legitimacy (and the cash) to get off of OTC, get more and better institutional investors, and to get rid of the funk that the swamp people have stained us with.